Granules India USFDA ADHD approvals set up FY27 growth

Why the latest USFDA approvals matter

Granules India Ltd has reported a series of regulatory updates centered on its US business, with a focus on central nervous system (CNS) and attention-deficit hyperactivity disorder (ADHD) products. The company said its subsidiary, Granules Pharmaceuticals Inc. (GPI), received US Food and Drug Administration (USFDA) approval for a generic version of a medication used to treat ADHD. Granules also highlighted a 180-day exclusivity period that it expects to benefit from after launch, describing it as an opportunity to capture additional market share.

Alongside product approvals, Granules pointed to multiple compliance milestones across manufacturing sites and regulatory filings. The company also said it anticipates better growth in FY27 and is awaiting approvals for six products in Europe. These updates collectively shape how investors assess the near-term execution path for product launches and the broader pipeline.

USFDA approval for Lisdexamfetamine chewable tablets

Granules said GPI received USFDA approval for its abbreviated new drug application (ANDA) for Lisdexamfetamine Dimesylate chewable tablets, a generic version of a medication used to treat ADHD. The approval was disclosed via an exchange filing, and Granules added that the ANDA was approved in the first review cycle.

While the excerpt does not provide launch timing, pricing, or competitive intensity, the first-cycle outcome is presented by the company as an operational milestone. The approval also reinforces Granules’ stated therapeutic focus areas, which include CNS and ADHD. Granules did not specify in the provided text whether the 180-day exclusivity benefit is linked to this product or to a different upcoming launch.

Additional US approvals: Amphetamine mixed salts

In a separate update, Granules India said it received USFDA approval for its generic amphetamine mixed salts indicated for the treatment of ADHD and narcolepsy. The approval was granted to Granules Pharmaceuticals, Inc (GPI), described as a wholly-owned arm.

The approval covers an ANDA for immediate release tablets in multiple strengths: 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, and 30 mg. The company disclosed this in a statement. This expands Granules’ presence in ADHD-related products through an additional molecule and a broad strength range.

Methylphenidate ER approval for narcolepsy

Granules India also disclosed that its subsidiary received USFDA approval for Methylphenidate Hydrochloride extended-release tablets used in the treatment of narcolepsy. The company said the USFDA approved the ANDA filed by Granules Pharmaceuticals, Inc through its US agent, First Time US Generics LLC.

The approved strengths mentioned are 10 mg and 20 mg. This approval aligns with the company’s stated focus on CNS and ADHD, and adds another narcolepsy-related product to its US pipeline. The excerpt does not include commercial launch details or expected revenue contribution.

180-day exclusivity: what the company flagged

Granules said it is set to benefit from a 180-day exclusivity period, calling it an essential opportunity to capture further market share once the product launches. The provided text does not identify which specific product the exclusivity relates to, nor does it describe the basis for exclusivity beyond the time period.

In the US generic market, such windows can matter because early entry may allow higher initial volumes or improved pricing versus later entrants. But the excerpt does not quantify impact or provide guidance linked to the exclusivity period. Investors typically look for clarity on launch readiness, supply assurance, and competitive entry timing, none of which are detailed in the provided text.

Q2FY26 regulatory milestones and filings

On the regulatory front, Granules said it achieved several milestones in Q2FY26. It reported three ANDA filings in the quarter. It also noted USFDA approval for Metformin IR Tablets (PAI), as stated in the excerpt.

Beyond approvals, Granules said it received Establishment Inspection Reports (EIRs) for the Bonthapally API Unit 1 and for Granules Pharmaceutical Inc. The company also reported a GMP certificate for its Gagillapur facility from German authorities. These are presented as steps that support compliance readiness across sites serving regulated markets.

Manufacturing sites: Gagillapur remediation and inspection outcomes

Granules said remediation work at the Gagillapur facility is progressing well with the USFDA. The excerpt does not detail the nature of the remediation, timelines, or the specific regulatory pathway for closure. Still, Granules pairing remediation progress with a GMP certificate from German authorities suggests it is tracking multiple regulator expectations across geographies.

The reported EIRs for Bonthapally API Unit 1 and Granules Pharmaceutical Inc are also relevant because EIRs generally follow inspections and document the agency’s inspection classification. The excerpt does not provide the inspection dates, classification, or any cited observations, so the discussion is limited to the fact that EIRs were received.

Europe pipeline: six approvals awaited

Granules said approvals for six products in Europe are awaited. The excerpt does not list the products, therapeutic areas, or expected timelines, but it signals that the company is pursuing expansion beyond the US portfolio updates.

Granules also stated that it focuses on CNS, ADHD, and oncology products. This focus is consistent with the US approvals disclosed in the excerpt, which relate to ADHD and narcolepsy.

Company profile and business model context

Granules India Limited is described in the excerpt as an Indian pharmaceutical manufacturing company headquartered in Hyderabad, Telangana. It is characterized as a vertically integrated pharmaceutical company manufacturing active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs), distributed to customers in regulated and semi-regulated markets.

The excerpt outlines three business areas: the core business of basic ingredients and PFIs including paracetamol, ibuprofen, metformin, guaifenesin, and methocarbamol; an emerging business focused on manufacturing APIs for customers with vertical integration; and a contract research and manufacturing business. As of December 2020, Granules had 35 ANDA approvals from the USFDA, and the excerpt notes penicillamine capsules as the latest approval on Dec. 3.

Wider CNS and narcolepsy landscape: a referenced approval

The provided text also includes a referenced regulatory entry for sodium oxybate (LUMRYZ), sponsored by Avadel CNS Pharmaceuticals LLC, with an approval date of September 26, 2024. The indication described is for cataplexy or excessive daytime sleepiness in adults with narcolepsy.

This reference does not state any direct link to Granules, but it provides context that narcolepsy therapies are active areas for regulatory decisions. Granules’ methylphenidate ER approval, as described earlier in the excerpt, sits within this broader CNS treatment landscape.

Key facts from the excerpt

Conclusion

Granules’ updates combine USFDA approvals in ADHD and narcolepsy-related products with a set of regulatory and compliance milestones across manufacturing sites. The company also flagged an upcoming 180-day exclusivity opportunity, while stating that it expects better growth in FY27 and is awaiting six Europe approvals.

The next concrete checkpoints, based on the excerpt, are progress on the Gagillapur remediation work with the USFDA and further outcomes on the pending Europe approvals. Investors will also track how the company translates the newly announced approvals into launches, within the constraints of the information Granules has publicly shared so far.